Clinical Trial Update: A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder [Phase 1]

View source ↗

Summary

A Phase 1 study to evaluate the tolerability of BI 3031185 in adults with borderline personality disorder or attention-deficit/hyperactivity disorder is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Borderline Personality Disorder

Drugs mentioned

• BI 3031185

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Borderline Personality Disorder, Attention Deficit Hyperactivity Disorder | Phase 1 | Status: RECRUITING